It is well established that folate requirements increase during pregnancy and that supplementing 0.4 mg folic acid/day to the general pregnant population is beneficial in terms of reducing the risk of neural tube defects (NTDs). Offspring of women with pregestational diabetes mellitus have an increased risk of congenital anomalies, including NTDs (1). In animal models, folic acid supplementation reduces glucose-induced congenital anomalies with a threshold effect (2). In humans, the protection afforded by folic acid supplementation against diabetes-associated birth defects is not clear: multivitamin supplements have been reported to reduce the risk of congenital anomalies, but the composition of the supplements was unknown and the benefit probably included that of overall prepregnancy care (3). In recent years, several academic societies (4,5) have recommended high doses of folic acid (4–5 mg/day) to diabetic pregnant women, based on their risk of congenital malformations. As folic acid–tolerable upper intake level is 1 mg/day, the aforementioned recommendations should be considered in the pharmacological range. High doses of folic acid can aggravate B12 vitamin deficiency and promote neoplasia (6), with diabetic women being at high risk (7). On the other hand, most diabetic women, even when planning pregnancy, do not take any folic acid supplement (8). We suggest that large efforts be made to ensure that, as one of the interventions of comprehensive prepregnancy care, diabetic women receive at least the folic acid dose recommended for the general population. When using high doses, we must take into account that they are in the pharmacological range, that there is no evidence of their benefit as a primary prevention strategy in diabetic pregnancy, and that side effects are potentially serious.

1.
Becerra JE, Khoury Mj, Cordero JF, Erickson JD: Diabetes mellitus during pregnancy and the risk for specific birth defects: a population-based case-control study.
Pediatrics
85
:
1
–9,
1990
2.
Wentzel P, Gäreskog M, Eriksson UJ: Folic acid supplementation disminishes diabetes- and glucose-induced dysmorphogenesis in rat embryos in vivo and in vitro.
Diabetes
54
:
546
–547,
2005
3.
Correa A, Botto L, Liu Y, Mulinare J, Erikson JD: Do multivitamin supplements attenuate the risk for diabetes-associated birth deffects?
Pediatrics
111
:
1146
–1151,
2003
4.
ACOG Committee on Practice Bulletins: ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists: number 44, July 2003 (replaces committee opinion number 252, March 2001).
Obstet Gynecol
102
:
203
–213,
2003
5.
Wilson RD, Davies G, Desilets V, Reid GJ, Summers A, Wyatt P, Young D, Genetics Committee and Executive and Council of the Society of Obstetricians and Gynaecologists of Canada: The use of folic acid for the prevention of neural tube defects and other congenital anomalies.
J Obstet Gynaecol Can
25
:
959
–973,
2003
6.
Kim YI: Will mandatory folic acid fortification prevent or promote cancer?
Am J Clin Nutr
80
:
1123
–1138,
2004
7.
Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK: Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria.
Diabetologia
49
:
945
–952,
2006
8.
Roland JM, Murphy HR, Ball V, Northcote-Wrightt J, Temple RC: The pregnancies of women with type 2 diabetes: poor outcomes but opportunities for improvement.
Diabet Med
22
:
1774
–1777,
2005